PARIS, March 15, 2023 /PRNewswire/ -- The European Medicines Agency has just granted an extension of the indication for the marketing authorisation for WAKIX® (pitolisant), which is now indicated for the treatment of narcolepsy in children from the age of 6 years, with or without cataplexy.
The European Medicines Agency (EMA) has approved Bioprojet’s Ozawade (pitolisant) for the treatment of excessive daytime sleepiness (EDS) associated with obstructive sleep apnoea (OSA) in adults.
Bioprojet`s Ozawade (pitolisant) Receives Approval in Europe
Bioprojet`s Wakix(pitolisant) receives market authorisation in EU for Narcolepsy